Valuation: Abivax

Capitalization 700.12Cr 808.45Cr 642.4Cr 604.4Cr 1.13TCr 77TCr 1.14TCr 7.64TCr 2.97TCr 37TCr 3.04TCr 2.97TCr 1,29600Cr P/E ratio 2026 *
-22.8x
P/E ratio 2027 * -25.4x
Enterprise value 651.67Cr 752.51Cr 597.95Cr 562.57Cr 1.05TCr 72TCr 1.06TCr 7.11TCr 2.77TCr 35TCr 2.83TCr 2.76TCr 1,20600Cr EV / Sales 2026 *
1,736x
EV / Sales 2027 * 72.4x
Free-Float
93.56%
Yield 2026 *
-
Yield 2027 * -
1 day+4.65%
1 week-22.53%
Current month-22.53%
1 month-16.73%
3 months-11.35%
6 months-6.84%
Current year-27.03%
1 week 60.45
Extreme 60.45
118.6
1 month 60.45
Extreme 60.45
118.6
Current year 60.45
Extreme 60.45
132
1 year 5.12
Extreme 5.12
132
3 years 4.51
Extreme 4.51
132
5 years 4.51
Extreme 4.51
132
10 years 3.87
Extreme 3.87
132
Manager TitleAgeSince
Chief Executive Officer 68 05/05/2023
Director of Finance/CFO - 02/01/2017
Chief Tech/Sci/R&D Officer - 19/03/2026
Director TitleAgeSince
Chairman - 16/08/2022
Chairman 68 05/05/2023
Director/Board Member 60 11/07/2023
Date Insider Type Main position Quantity % Market Cap.
21/05Fiscal year

Chief Executive Officer

35,456 0.0447%
23/03Fiscal year

Chief Executive Officer

35,456 0.0448%
20/02Free

Director

2,471 0.0032%
Change 5d. change 1-year change 3-years change Capi.($)
+4.65%-22.53%+1,153.21%+394.09% 808.45Cr
-1.18%-2.96%-13.53%-15.84% 4.27TCr
-4.15%-5.24%+271.22%+477.96% 3.17TCr
-1.84%+0.68%+24.48%-10.08% 3.06TCr
-3.51%-6.19%+5.10%+21.75% 3TCr
-2.89%-6.70%+14.76%+14.13% 2.42TCr
-3.83%-6.10% - - 1.31TCr
-0.18%+3.94%+13.97%+7.09% 1.32TCr
-0.97%+1.60%+54.73%+109.79% 1.3TCr
-0.87%-2.64%+111.35%+76.24% 1.23TCr
Average -1.48%-4.61%+181.70%+119.46% 2.19TCr
Weighted average by Cap. -2.06%-3.85%+101.42%+101.13%

Financials

2026 *2027 *
Net sales 37.53L 43.34L 34.44L 32.4L 60.35L 41Cr 61.29L 4.09Cr 1.59Cr 20Cr 1.63Cr 1.59Cr 69Cr 9.01Cr 10Cr 8.27Cr 7.78Cr 14Cr 991.39Cr 15Cr 98Cr 38Cr 479.44Cr 39Cr 38Cr 1.67TCr
Net income -27Cr -31Cr -24Cr -23Cr -43Cr -2.94TCr -44Cr -291.05Cr -113.27Cr -1.42TCr -115.7Cr -113.19Cr -4.94TCr -21Cr -25Cr -20Cr -19Cr -35Cr -2.37TCr -35Cr -234.45Cr -91Cr -1.14TCr -93Cr -91Cr -3.98TCr
Net Debt -48Cr -56Cr -44Cr -42Cr -78Cr -5.33TCr -79Cr -528.38Cr -205.64Cr -2.58TCr -210.05Cr -205.48Cr -8.97TCr -48Cr -56Cr -44Cr -42Cr -78Cr -5.31TCr -79Cr -526.54Cr -204.92Cr -2.57TCr -209.32Cr -204.77Cr -8.93TCr
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
05/26/05 87.85 +4.65% 5,30,615
04/26/04 83.95 +17.82% 7,06,575
03/26/03 71.25 +12.92% 10,08,671
02/26/02 63.10 -43.56% 16,81,840
01/26/01 111.80 -1.41% 4,21,509
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
87.85EUR
Average target price
114.77EUR
Spread / Average Target
+30.64%

Quarterly revenue - Rate of surprise